No Data
No Data
Porton Pharma Solutions' Factory Passes US FDA Inspection
Porton Pharma Solutions (300363.SZ): Chongqing Changshou plant passes on-site inspection by the USA FDA.
On July 16th, Gelonghui reported that Porton Pharma Solutions (stock code: 300363.SZ) announced that its Chongqing Changshou plant underwent an on-site inspection of current Good Manufacturing Practices (cGMP) by the United States Food and Drug Administration (FDA) from March 25th to 29th, 2024. The inspection covered quality, production, material management, and laboratory control systems. Recently, the company received the Establishment Inspection Report (EIR) from the FDA. The company passed the inspection with zero defects ("0-483").
Two executives of Porton Pharma Solutions (300363.SZ) plan to spend between 0.6 million yuan and 1 million yuan to increase their shareholdings.
Porton Pharma Solutions (300363.SZ) announced that Chen Hui, deputy general manager and financial officer of the company, and the deputy general manager and director...
Porton Pharma Solutions Ltd.'s (SZSE:300363) Stock Price Dropped 9.3% Last Week; Retail Investors Would Not Be Happy
Boteng Co., Ltd. (300363.SZ): 2023 equity distribution, 10 distributions of 4.87 yuan, share registration date May 28
On May 22, Ge Longhui Co., Ltd. (300363.SZ) announced that the company's 2023 equity distribution plan is to distribute RMB 4.870,000 in cash (tax included) to all shareholders for every 10 shares based on the company's current total share capital excluding the 3,282,344 shares that have already been repurchased. The share registration date for this equity distribution is May 28, 2024, and the ex-dividend date is May 29, 2024.
Boteng Co., Ltd. (300363.SZ): Can provide CDMO services for different types of drugs and therapies such as small molecule drugs, large molecule drugs, and gene cell therapy
Gelonghui, May 10 | Boteng Co., Ltd. (300363.SZ) said on the investor interactive platform that the company is a pharmaceutical R&D and production outsourcing organization (CDMO) that provides full-category, end-to-end services for pharmaceutical companies, biotechnology companies, scientific research institutions, etc. on a global scale, and can provide CDMO services for different types of drugs and therapies such as small molecule drugs, large molecule drugs, and gene cell therapy. The company continues to invest in R&D resources to establish an interdisciplinary innovative technology platform covering drug crystallization, biocatalysis, fluid chemistry, micronized powders, highly active drugs, preparation chromatography, fluorine chemistry, photochemistry,
No Data